According to a new report published by Allied Market Research, titled, “Cephalosporin Market by Generation, Type, Route of Drug Administration, and Application: Opportunity Analysis and Industry Forecast, 2019โ€“2027,” the global cephalosporin market size was valued at $13.69 billion in 2019, and is estimated to reach $16.87 billion by 2027, growing at a CAGR of 2.6% from 2019 to 2027. The third-generation cephalosporin segment held more than 32% of the total cephalosporin market share in 2019.

๐‹๐ข๐ฌ๐ญ ๐จ๐Ÿ ๐Š๐ž๐ฒ ๐๐ฅ๐š๐ฒ๐ž๐ซ๐ฌ :

The report provides a comprehensive analysis of the key players operating in the global cephalosporin industry, Allergan Plc., Bristol-Myers Squibb Company, F.Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Lupin Limited (Lupin Pharmaceuticals, Inc.), Merck & Co. Inc., Novartis International AG, Pfizer Inc., Sanofi, and Teva Pharmaceutical Industries Ltd. The other players in the value chain include Eli Lilly and Company, Bayer HealthCare, Sun Pharmaceutical, Shionogi, and others.

๐ƒ๐จ๐ฐ๐ง๐ฅ๐จ๐š๐ ๐’๐š๐ฆ๐ฉ๐ฅ๐ž ๐‘๐ž๐ฉ๐จ๐ซ๐ญ

๐Š๐„๐˜ ๐…๐ˆ๐๐ƒ๐ˆ๐๐†๐’ ๐Ž๐… ๐“๐‡๐„ ๐’๐“๐”๐ƒ๐˜

  • Generic cephalosporin segment is expected to register the highest CAGR of 3.1% during the analysis period.
  • Based on route of administration, the intravenous cephalosporin segment accounted for the largest share in 2019 and is expected to maintain its dominance during the forecast period.
  • India and China collectively contributed for more than 40% share of the Asia-Pacific cephalosporin market in 2019.
  • U.S. was the major shareholder that accounted for more than 90% of the North America cephalosporin market in 2019.

๐—–๐—ผ๐˜ƒ๐—ถ๐—ฑ-๐Ÿญ๐Ÿต ๐—ฆ๐—ฐ๐—ฒ๐—ป๐—ฎ๐—ฟ๐—ถ๐—ผ:

Economies across the world are suffering from the impact of COVID-19 and many industries are experiencing losses. However, pharmaceutical companies have a center stage in the COVID-19 fight and are responding to rapid challenges arising from disturbances in supply chains and need to change business processes. If this pandemic lasts for a medium or long span of time, it may impact supply of active material and ingredients (mainly from China) as well as import and export of pharmaceuticals. However, the virus damages cells so badly that it becomes easier for certain bacteria to cause secondary infections, for instance, pneumonia in influenza patients, which can be treated with antibiotics and in such cases health care providers recommend cephalosporin as well as combination therapies of antibiotics. Hence, the impact of COVID-19 on cephalosporin industry is expected to be moderate.

๐…๐จ๐ซ ๐๐ฎ๐ซ๐œ๐ก๐š๐ฌ๐ž ๐ˆ๐ง๐ช๐ฎ๐ข๐ซ๐ฒ

Based on application, the market is segmented into respiratory tract infection, skin infection, ear infection, urinary tract infection, sexually transmitted infection, and others. The respiratory tract infection segment generated the highest revenue in 2019 and is anticipated to maintain its dominance throughout the forecast period, as cephalosporin are used for treatment of both upper & lower respiratory tract infection and lower respiratory infections are the leading infectious causes of death globally. Hence, oral cephalosporin is used in the treatment of lower and upper respiratory tract infections widely. However, the sexually transmitted infection is expected to register highest CAGR during the forecast period, due to the rising rate of sexually transmitted infections globally and some second-generation cephalosporin and most of the third-generation cephalosporin are effective in the treatment.

Based on generation, the market is classified into first-generation cephalosporin, second-generation cephalosporin, third-generation cephalosporin, fourth-generation cephalosporin, and fifth-generation cephalosporin. The third-generation cephalosporin segment generated the highest revenue in 2019 and is anticipated to maintain its dominance throughout the forecast period, as these have a broader spectrum of activity and these are used for the treatment of Gram-negative bacillary meningitis, serious infections of enterobacteriaceae, otitis media, and others. However, the fifth-generation cephalosporin is expected to register highest CAGR of 3.9% during the forecast period.

๐—š๐—ฒ๐˜ ๐——๐—ฒ๐˜๐—ฎ๐—ถ๐—น๐—ฒ๐—ฑ ๐‘๐ž๐ฉ๐จ๐ซ๐ญ

๐Ž๐ญ๐ก๐ž๐ซ ๐“๐ซ๐ž๐ง๐๐ข๐ง๐  ๐‘๐ž๐ฉ๐จ๐ซ๐ญ๐ฌ:

Enzymes Market

Africa Large Volume Parenterals (LVP) Market

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of โ€œMarket Research Reportsโ€ and โ€œBusiness Intelligence Solutions.โ€ AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.


David Correa
5933 NE Win Sivers Drive
205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975

Leave a comment

Your email address will not be published. Required fields are marked *